|
Basic Characteristics of Mutations
|
|
Mutation Site
|
V236M |
|
Mutation Site Sentence
|
We evaluated the impact of the V236M mutation in the UL56 gene alone and in combination with the E756K mutation in the UL54 gene on drug susceptibility and viral replicative capacity of recombinant human cytomegalovirus. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL56 |
|
Standardized Encoding Gene
|
UL56
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
GCV;LMV;FOS;CDV;BCV |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
28807919
|
|
Title
|
Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes
|
|
Author
|
Piret J,Goyette N,Boivin G
|
|
Journal
|
Antimicrobial agents and chemotherapy
|
|
Journal Info
|
2017 Oct 24;61(11):e01044-17
|
|
Abstract
|
Letermovir is an investigational antiviral agent with a novel mechanism of action involving the viral terminase (pUL56). We evaluated the impact of the V236M mutation in the UL56 gene alone and in combination with the E756K mutation in the UL54 gene on drug susceptibility and viral replicative capacity of recombinant human cytomegalovirus. The double mutant exhibited at least borderline resistance to all antivirals tested (ganciclovir, foscarnet, cidofovir, brincidofovir, and letermovir) and replicated less efficiently than the wild-type virus in vitro.
|
|
Sequence Data
|
-
|